Telix Pharmaceuticals Ltd — Board/Management Information 2023

Dec 19, 2023

==> picture [156 x 65] intentionally omitted <==

Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia

ASX RELEASE

Appointment of Dr David Cade to Group Chief Medical Officer

Melbourne (Australia) – 20 December 2023 . Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. David Cade as Group Chief Medical Officer (CMO), effective 1 January 2024. He succeeds outgoing Group CMO Dr. Colin Hayward, who has taken the decision to step down from his role effective 31 December, to pursue other interests.

Dr. Cade is an experienced CMO who joined Telix in October 2019. Prior to joining Telix David most recently served as the CMO at Cochlear Limited, and Sirtex Medical Limited, where he led numerous pivotal phase 3 oncology trials across large disease areas. During his time at Telix he has served in a range of senior executive roles and is currently Chief Executive Officer of Telix’s Asia-Pacific (APAC) business[1] . He has previously served as Chief Business Officer and Head of Investor Relations at Telix. David has led multiple strategic transactions for Telix, including the China Grand Pharma partnership, and subsequently oversaw the approval of Illuccix® by the Therapeutic Goods Administration (TGA) in Australia.

David brings deep experience in oncology, interventional radiology and nuclear medicine therapeutic areas. He holds a Bachelor of Medicine / Bachelor of Surgery from Monash Medical School and a Master of Business Administration from Melbourne Business School and ESADE Business and Law School. He is also a Graduate of the Australian Institute of Company Directors.

Dr. Christian Behrenbruch, Managing Director and Group CEO commented on the leadership succession, “I would firstly like to thank our outgoing CMO Colin Hayward for his immense contribution to Telix. I have thoroughly enjoyed working with Colin over the last three years as we have progressed our therapeutic pipeline to the point where we can commence phase 3 studies. His strategic oncology domain knowledge and immense skills in early-stage clinical translation have served the Company well during a period of significant growth. Colin’s establishment of a leading medical affairs team has been instrumental to the successful launch of Illuccix® in the United States. I wish Colin every success in his future activities.

“In the appointment of our next Group CMO, we sought an executive with both pharmaceutical business development and market access experience, combined with extensive experience in operationalising late-stage global clinical trials. In David we have a long-tenured and highly versatile internal candidate with extensive international experience and the depth of understanding of Telix’s business and clinical leadership expertise to take our clinical programs to the next level. I am looking forward to working with David in his new role to accelerate Telix’s therapeutic portfolio towards the clinic.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

1 ASX disclosure 3 May 2021

Page 1

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn and X.

Telix’s lead imaging product, gallium-68 ([68] Ga) gozetotide injection (also known as[68] Ga PSMA-11 and marketed under the brand name Illuccix[®] ), has been approved by the U.S. Food and Drug Administration (FDA),[2] by the Australian Therapeutic Goods Administration (TGA),[3] and by Health Canada.[4]

Telix Investor Relations

Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

2 Telix ASX disclosure 20 December 2021.

3 Telix ASX disclosure 2 November 2021.

4 Telix ASX disclosure 14 October 2022.

Page 2